ORGS - Orgenesis Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.10
+0.02 (+0.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.08
Open5.04
Bid5.00 x 900
Ask6.10 x 800
Day's Range5.04 - 5.30
52 Week Range3.87 - 12.41
Volume106,767
Avg. Volume29,005
Market Cap79.667M
Beta (3Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Does Orgenesis Inc.’s (NASDAQ:ORGS) CEO Pay Compare Well With Peers?
    Simply Wall St.14 days ago

    Does Orgenesis Inc.’s (NASDAQ:ORGS) CEO Pay Compare Well With Peers?

    In 2013 Vered Caplan was appointed CEO of Orgenesis Inc. (NASDAQ:ORGS). First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider theRead More...

  • GlobeNewswirelast month

    Orgenesis Reports 85% Increase in Revenue and 139% Increase in Gross Profit for Fiscal 2018

    Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today reported financial results and provided a business update for the fiscal year ended November 30, 2018.

  • GlobeNewswirelast month

    Orgenesis CEO to Participate in Panel at the 2019 BIO CEO & Investor Conference

    Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Vered Caplan, Chief Executive Officer, will participate in a panel, “New Treatments for Diabetes and Obesity: Innovations for Chronic Diseases,” at the 2019 BIO CEO & Investor Conference. The panel will be held on Tuesday, February 12th, 2019 at 9:00 AM, Eastern Time, at the New York Marriott Marquis. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies.  The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

  • GlobeNewswirelast month

    Orgenesis’ CSO Sara Ferber to Present to the International Research Training Group Hosted by Technische Universität Dresden and the King's College London

    Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced that Orgenesis’ Chief Scientific Officer, Sara Ferber Ph.D. will present the Company's novel and proprietary autologous trans-differentiation cell therapy technologies for the treatment of diabetes at The International Research Training Group (IRTG) 2251 "Immunological and Cellular Strategies in Metabolic Disease" (ICSMD) retreat which is being held on February 4-7th, 2019 at King’s College London.

  • GlobeNewswirelast month

    Orgenesis Announces the Opening of New Offices and Laboratories at Accessia Pharma in Liège, Belgium to Support its Point of Care Cellular Therapy Platform

    Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced the opening of new offices and laboratories at Accessia Pharma in Liège, Belgium for its Belgian subsidiary, Orgenesis SPRL, in order to support its Point of Care (“POCare”) Cellular Therapy platform. Orgenesis is supported by its partners: Theracell (Greece), Hemogenyx (UK), Serpin (USA), to further expand cellular therapy development in the Walloon Region of Belgium.

  • GlobeNewswire2 months ago

    Orgenesis Announces U.S. Expansion of Masthercell Global Subsidiary

    Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that its subsidiary, Masthercell Global Inc. (“Masthercell Global”), is expanding into the United States and has executed a lease agreement to build a new 30,000 sq. ft manufacturing facility in Houston, Texas.  The new facility will allow Masthercell Global to expand its world presence and current capacities.  Masthercell Global is a leading cell and gene therapy Contract Development and Manufacturing Organization (“CDMO”) that will now have operations and manufacturing facilities across three continents (North America, Europe and Asia).

  • GlobeNewswire2 months ago

    Orgenesis Subsidiary Atvio Biotech to Present at Phacilitate Leaders World 2019 Conference

    Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Dr. Ohad Karnieli, Ph.D., MBA, from Atvio Biotech Ltd. management, which is wholly-owned by Orgenesis’ Masthercell Global subsidiary, will be presenting at the Phacilitate Leaders World 2019 Conference.  The presentation will be held on Thursday, January 24, 2019 at 3:50 p.m. Eastern Standard Time at the Hyatt Regency Miami. The presentation is entitled, "Bringing cell therapy to the point of care, automation, analytics and everything between.”  The Company will also host a booth (#804) throughout the duration of the event.

  • GlobeNewswire3 months ago

    Orgenesis CEO Selected to Participate in Cell and Gene Therapy Workshop at Biotech Showcase 2019 in California

    Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Vered Caplan, Chief Executive Officer, has been selected to participate in a workshop entitled “Cell and gene therapy: The financing surge” at the 2019 Biotech Showcase. Vered Caplan has been invited to discuss how disruptive therapeutic products have shifted the investment and financial landscape within the Gene and Cell Therapy sector. Orgenesis is a vertically integrated developer, manufacturer and service provider in the cell and gene therapy industry.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Dec. 31, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Orgenesis Announces Collaboration with MangoGen Pharma for Advanced Gene Delivery Platform

    Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced a collaboration with MangoGen Pharma Inc. (MangoGen), initially focused on the pre-clinical development of insulin producing cells (IPC) using MangoGen’s advanced gene delivery platform. Under this initial collaboration, the companies will work together to develop a complete solution for the delivery of IPC cells to murine animal models. The Company also announced that it has been awarded a grant from the Canada-Israel Industrial R&D Foundation (CIIRDF) to fund this project.

  • GlobeNewswire3 months ago

    Orgenesis CEO Vered Caplan to Appear on Fox Business Network’s “Mornings with Maria”

    Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced that Vered Caplan, CEO of Orgenesis, will appear as a guest on Fox Business Network’s Mornings with Maria at approximately 6:50 AM, Eastern Time this morning to discuss the Company’s new point-of-care (POCare) model, customer base and revenue growth, as well as other developments at the Company and within the regenerative medicine industry. The segment can be viewed live on the Fox Business Channel and will be available online and for replay at https://www.foxbusiness.com/fbntv.

  • GlobeNewswire3 months ago

    Orgenesis CEO Vered Caplan to Present at William Blair’s Biotech Focus Day Series: Cell and Gene Therapy Manufacturing

    Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider today announced that Vered Caplan, CEO of Orgenesis, will participate in William Blair’s Biotech Focus Day Series: Cell and Gene Therapy Manufacturing, which will combine experts and leading companies involved in the rapid expansion of potentially curative therapies and the logistical hurdles in their development. Ms. Caplan will provide a morning presentation entitled, “Thinking inside the box: centralized vs decentralized manufacturing.” Ms. Caplan will also participate in a midday panel discussion of current issues in manufacturing including scale up, automation, release specifications, and commercial logistics.  The panel discussion will feature senior executives of leading companies in the cell and gene therapy and manufacturing sectors, including LogicBio Therapeutics, Rocket Pharmaceuticals, and Celyad.

  • GlobeNewswire3 months ago

    Orgenesis Announces Collaboration with Ben-Gurion University to Research and Develop Dissolvable Carriers for Cell Culturing

    GERMANTOWN, Md. and BEER-SHEVA, Israel, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (ORGS), a developer of advanced cell therapies, manufacturer and service provider, along with BGN Technologies an affiliate of Ben-Gurion University of the Negev (BGU), today announced a licensing and collaboration agreement on the research and development of BGU’s dissolvable carriers for cell culturing. The technology was developed by Professor Smadar Cohen, Founder and Director of The Regenerative Medicine and Stem Cell (RMSC) Research Center at BGU. Under the license agreement, Orgenesis has received the exclusive, worldwide rights to make, develop and commercialize technologies utilizing the dissolvable carriers for cell culturing.

  • GlobeNewswire4 months ago

    Orgenesis Announces that Dr. Ohad Karnieli, CEO of Atvio Biotech, a Wholly-Owned Subsidiary of Masthercell Global, will Present at the Cell Therapy Manufacturing & Gene Therapy Congress

    GERMANTOWN, Md., Dec. 03, 2018 -- Orgenesis Inc. (NASDAQ: ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Dr. Ohad.

  • GlobeNewswire4 months ago

    Orgenesis Subsidiary Masthercell Global Expands Production and Doubles its Capacity

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its subsidiary, Masthercell Global (“Masthercell”), a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO), has launched a new production wing of 600 square meters at its Belgium site in the presence of Belgium’s Public Health and Social Affairs Minister, Maggie De Block, and the Minister-President of Wallonia, Willy Borsus. Masthercell is also backed by Great Point Partners, LLC (“GPP”), a leading healthcare investment firm based in Greenwich, Connecticut.

  • How Does Orgenesis Inc (NASDAQ:ORGS) Affect Your Portfolio Volatility?
    Simply Wall St.4 months ago

    How Does Orgenesis Inc (NASDAQ:ORGS) Affect Your Portfolio Volatility?

    If you own shares in Orgenesis Inc (NASDAQ:ORGS) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...

  • GlobeNewswire5 months ago

    Orgenesis CEO Vered Caplan to Appear Live Today on ‘Midday Movers’ on Yahoo Finance

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Vered Caplan, CEO of Orgenesis, will appear as a guest on ‘Midday Movers’ on Yahoo Finance this morning at 12:15 PM Eastern Time to discuss the Company’s new point-of-care (POCare) model, customer base and revenue growth, as well as other developments at the Company and within the regenerative medicine industry.

  • How Orgenesis is breaking barriers in biotech
    Yahoo Finance Video5 months ago

    How Orgenesis is breaking barriers in biotech

    Yahoo Finance's Seana Smith and Adam Shapiro talks to Vered Caplan, CEO of Orgenesis, about making it to the top in a male-dominated field, and how her company is making a name for itself in the world of biotechnology.